Nayara closes preseed round led by SFC Capital
This article covers Nayara, a healthtech startup that has closed a pre-seed funding round led by SFC Capital. The funding will support development, clinical validation and commercial expansion of its clinical-grade AI companions, which aim to support patients between appointments and help hospitals, health systems and medtech providers manage routine patient contact outside hospitals.
Nayara, a healthtech startup, has closed a pre-seed funding round led by SFC Capital. The London-based company builds clinical-grade AI companions that support patients between appointments, and the fresh capital will be used to accelerate product development, clinical validation and commercial expansion. The round matters because Nayara targets routine patient contact that happens outside hospitals — the company says about 90% of care — where clinicians often have limited visibility.
Why it matters
Healthcare delivery increasingly depends on what happens between clinic visits, from symptom monitoring to emotional support. Nayara’s technology aims to reduce the burden of routine enquiries on clinical teams while flagging concerns that need clinician attention. If it works at scale, that could free clinicians to focus on higher‑acuity work and improve follow-up for more patients without proportionally increasing staff.
The announcement frames the service as a tool for hospitals, health systems and medtech companies to handle routine patient questions, provide personalised guidance and check in on progress outside the clinic. Early use across clinical pathways, including a breast cancer companion, indicates early traction in oncology where continuity of care is especially important.
Inside the product
Nayara deploys conversational AI “companions” that answer routine queries, offer personalised advice and deliver emotional support. The platform also triages responses, identifying issues that need escalation and routing them to the appropriate clinical team. That combination of automated engagement and escalation aims to reduce repetitive enquiries while giving clinicians clearer visibility of patient status between appointments.
The company says its technology is already used across clinical pathways, with a breast cancer companion that has supported hundreds of patients. That early clinical use will be central to the company’s stated priorities: product development, formal clinical validation and commercial roll‑out with health system partners.
Who are the investors?
The round was led by SFC Capital. No other investors or the total amount raised were disclosed.
In the announcement, Adam Beveridge, Fund Principal, SFC Capital, said:
We see tremendous potential in Nayara's vision and the team's ability to execute. As healthcare systems face mounting pressure, solutions that can deliver meaningful improvements for both patients and providers represent an exciting investment opportunity. We're delighted to support Nayara in its next stage of growth.
SFC Capital is known for backing early-stage UK technology companies. Its participation signals continued investor interest in products that shift routine care outside the clinic and apply AI to patient engagement and triage.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
Nayara was co-founded by Gal Moore, CEO, and Rami Kahan, Chief Commercial Officer. The founding team describes itself as a mix of medical professionals, patients, carers and AI engineers, reflecting an emphasis on clinical relevance and user experience.
In the announcement, Gal Moore, Co-founder & CEO at Nayara, said:
Technology has transformed what medicine can achieve, but the way we support patients has struggled to keep pace. We started Nayara with a simple belief: no patient should feel alone in their healthcare journey. No warning sign should go unaddressed because the clinical team lacked the information, or the time, to act.
That framing positions Nayara as a clinical‑first product rather than a purely consumer chatbot, and it signals a focus on formal validation and integration with clinical workflows.
The bigger picture
This funding round is part of a broader trend of interest from healthtech investors in tools that extend care beyond hospital walls and improve patient follow-up. UK health systems are under operational strain, and technologies that can safely automate routine touchpoints and surface actionable signals to clinicians are receiving growing attention.
Nayara’s next steps — scaling clinical trials, proving health outcomes and integrating with provider systems — will determine whether its AI companions move from early deployments to routine use across NHS and private providers in the UK and Europe.
They've invested in Nayara
Get to know these healthtech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 SFC Capital( ) SFC Capital is a venture capital firm that focuses on investing in early-stage t... London  | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK